

Supplementary Material for

Isolation of Intracellular Proteinase Inhibitors Derived from Designed Ankyrin Repeat Proteins by Genetic Screening


Martin Kawe, Patrik Forrer, Patrick Amstutz[#], and Andreas Plückthun

Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich

Running Title: Designed Ankyrin Repeat Protein Libraries as Source for Intracellular Inhibitors

Address correspondence to: Andreas Plückthun, Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8050 Zürich, Tel. +41 44 635 55 70, Fax +41 44 635 57 12, E-Mail: plueckthun@bioc.unizh.ch)

[#]Present address: Molecular Partners AG, c/o Institute of Biochemistry University of Zürich; Winterthurerstrasse 190, CH-8057 Zürich



Supplemental Figure S1 - Vector map of the plasmid vector pMAKcl-T- ω -DL. ORFs are depicted as arrows, terminator sequences are indicated by a blue line, the NIa^{pro} recognition sequence and the His₆ tags are depicted as perpendicular blue lines and promoter regions are indicated by brown arrows.

Materials and Methods

Plasmids - Plasmids used in this study are listed in Table 1 in the main text. The sequences of all inserts in plasmids that were generated by PCR were confirmed by DNA sequencing.

The vector for the expression of NIa^{pro} proteinase in all *in vivo* experiments, pZA55-

TEV, was constructed by inserting the PCR amplified *araC* gene plus P_{BAD} promoter sequence into pZA21-TEV, thereby replacing its *XhoI/HindIII* fragment. The *araC* gene-P_{BAD} promoter sequence was amplified from pBADGFPAC2 with oligonucleotides MAK_#34F (5'-ATCCGCTCGAGGCATAATGTGCCTGTC-3') and MAK_#34R (5'-ATCCCAAGCTTTCTCCCATATGTATATC

TCC-3'), and the product was cloned with the restriction enzymes *XhoI* and *HindIII* into pZA21-TEV. In turn, pZA21-TEV was constructed by inserting the PCR amplified gene of the catalytic domain of NIa^{pro} proteinase into pZA21, thereby replacing its *KpnI/BamHI* fragment. The gene of the catalytic domain of NIa^{pro} proteinase was amplified from pRK793 with oligonucleotides MAK_#28F (5'-ATTATGGTACCATGGGAGAAAGCTTGT TTAAGG-3') and MAK_28R (5'-GCAAGGCGATTAAGTTGGGTAACGC-3') and the product was inserted with the restriction enzymes *KpnI* and *BamHI* into pZA21, thus generating pZA21-TEV). The *SacI/AatII* fragment of this cloning intermediate was replaced by inserting the PCR amplified Tc^R resistance gene. The Tc^R resistance gene was amplified from pTRG with oligonucleotides MAK_#40F (5'-TATACGAGCT CCATTCAGGT CGAGGTGG-3') and MAK_#40R (5'-TATAGGACGT CTATTTTTTT GATGGGAAGG C-3') and the product was cut with the restriction enzymes *SacI* and *AatII* and ligated, thus generating pZA55-TEV.

pBRcI-T- ω is a derivative of pBRcI- ω containing a NIa^{pro} cleavage site. It was constructed by ligating insert 1 and insert 2 (see below) simultaneously into pBRcI- ω , thereby replacing its *NotI/SalI* fragment. Insert 1 is a synthetic oligonucleotide duplex (5'-ATAAGAATGC GGCCGCTGGC TCGAGCGGTT CAGGCACTGA AAATCTTTAT TTTCAATCAG GTGCTAGCTA G-3') cut with the restriction enzymes *NotI* and *NheI*. Insert 2 was a PCR amplicon of the RNAP- ω gene from pBRcI- ω with oligonucleotides MAK_#29F (5'-TCTAGCTAGC CATCATCATC ATCATCATGG CTCTGCACGC GTAAGTGTTC AGG-3') and MAK_#29R (5'-ATATGTCGAC TTAACGACGA CCTTCAGC -3') and the product was cut with the restriction enzymes *NheI* and *SalI* and ligated together with insert 1, thus generating pBRcI-T- ω .

pMAKcI-T- ω -pD is a derivative of pQI-pD and constitutively expresses the λ cI-T- ω fusion protein under control of the β -lactamase promoter P_{bla}. It was constructed by inserting the PCR amplified λ cI-T- ω gene into pQI cut

by *SspI*. The λ cI-T- ω gene was amplified from pBRcI-T- ω with oligonucleotides MAK_#41F (5'- GCTGTTAATA TTGAAAAAGG AAGAGTATGA GCACAAAAAA GAAACC -3') and MAK_#41R (5'- GGTAGCAATA TTTTAACGAC GACCTTCAGC -3'), and the product was digested blunt ended with the restriction enzymes *SspI* and ligated into pQI.

pMAKcI-T- ω -DL is a derivative of pMAKcI-T- ω -pD and contains the pool of DARPins enriched by ribosome display, binding NIa^{pro} proteinase. It was used in all *in vivo* screening experiments. The ORFs of the ribosome-display-selected DARPIn proteins were digested with *NcoI* and *HindIII* and ligated into pMAKcI-T- ω -pD, yielding the selection plasmid ready for *in vivo* screening.

pMAKcI-T- ω -DL-tag is a derivative of pMAKcI-T- ω -DL and was used for the DARPins 9_1s, 13_1b, 20_2b and E2_5 in the western blot experiments. In this vector the DARPIn genes lack their N-terminal RGS-His₆ tag. Each was constructed by cutting out the DARPIn gene from pMAKcI-T- ω -DL with restriction enzymes *BamHI* and *HindIII* and inserting this fragment into pQE60, thus replacing its *BamHI/HindIII* fragment. This intermediate cloning construct was cut by restriction enzymes *EcoRI* and *HindIII*, and the fragment containing the DARPIn gene was placed back into pMAKcI-T- ω -DL, thus replacing its *EcoRI/HindIII* fragment.

pAT223-TEV is a derivative of pAT223 and was used for the expression of His-tagged biotinylated and non-biotinylated gpD- NIa^{pro} proteinase fusion protein. It was constructed by inserting the PCR amplified NIa^{pro} proteinase gene into pAT223, thereby replacing its *BamHI/HindIII* fragment. The NIa^{pro} proteinase gene was amplified from pRK793 with oligonucleotides MAK_#31F (5'- CGCGGATCCA TGGGAGAGAG CTGTGTTAAG GGG -3') and MAK_#31R (5'- ATCCCAAGCT TTTATTAGCG ACGGCG -3') and the product was cloned with the restriction enzymes *BamHI* and *HindIII* into pAT223.